EntryPoint Capital LLC Reduces Position in Insmed Incorporated (NASDAQ:INSM)

EntryPoint Capital LLC trimmed its position in Insmed Incorporated (NASDAQ:INSM) by 41.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,252 shares of the biopharmaceutical company’s stock after selling 2,311 shares during the quarter. EntryPoint Capital LLC’s holdings in Insmed were worth $225,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jennison Associates LLC lifted its holdings in Insmed by 0.6% in the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after buying an additional 4,560 shares during the period. Capital CS Group LLC purchased a new stake in Insmed in the fourth quarter worth $586,000. Orion Portfolio Solutions LLC boosted its holdings in Insmed by 48.5% in the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 9,170 shares in the last quarter. Tidal Investments LLC increased its position in Insmed by 447.0% during the 3rd quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company’s stock valued at $1,759,000 after purchasing an additional 19,696 shares during the period. Finally, Harbor Capital Advisors Inc. raised its holdings in Insmed by 237.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company’s stock worth $4,115,000 after purchasing an additional 41,918 shares in the last quarter.

Insmed Stock Up 0.4 %

INSM stock opened at $77.99 on Friday. The stock has a market capitalization of $14.12 billion, a P/E ratio of -13.95 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The business has a fifty day moving average price of $78.18 and a 200-day moving average price of $73.99.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

INSM has been the topic of several research analyst reports. UBS Group boosted their price target on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, February 21st. Morgan Stanley raised their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their price target on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Insider Buying and Selling

In other news, CEO William Lewis sold 18,750 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the transaction, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at $26,885,606.40. This represents a 4.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares of the company’s stock, valued at $6,773,307.06. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 550,957 shares of company stock worth $42,992,528. 4.60% of the stock is owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.